Genetic Factors Responsible for Alzheimer's Disease Identified
By LabMedica International staff writers Posted on 16 Jan 2018 |
Image: Researchers have identified genes that could be precursors to Alzheimer’s disease, which could be targets for new treatments that may delay or prevent the onset of the disease (Photo courtesy of Medical News Today).
Several new genes have been identified that are responsible for Alzheimer's disease (AD) including those leading to functional and structural changes in the brain and elevated levels of AD proteins in cerebrospinal fluid (CSF).
A new study focused on individual groups across specific on the cognitive spectrum: normal cognitive functioning or controls, mild cognitive impairment (MCI) and AD cases. As opposed to the typical study design, which combines all such persons into a single group or focuses only on cognitively healthy persons, a new study identified several novel genetic associations within multiple subgroups.
A team of scientists led by those at Boston University School of Medicine (Boston, MA, USA) conducted genome-wide association studies for AD-related endophenotypes including hippocampal volume, logical memory scores, and CSF. They tested the association between AD-related brain MRI measures, logical memory test scores and CSF levels of two AD proteins amyloid-beta (Aβ42) and tau with several million genetic markers called single-nucleotide polymorphisms (SNPs) across the genome in a sample of 1,189 participants of the Alzheimer Disease Neuroimaging Initiative (ADNI) study. They then examined the biological significance of the top-ranked associated SNPs and genes using several datasets containing information about gene expression in parts of the brain most affected by AD.
The scientists found that two of the study-wide significant genes identified in the normal cognitive functioning group, Serine/Arginine Repetitive Matrix 4 (SRRM4) and Microtubule Associated Scaffold Protein 1(MTUS1), are involved in neuronal signaling, development and loss. Another gene identified in this group, Glutamate Ionotropic Receptor NMDA Type Subunit 2B (GRIN2B), encodes a subunit of a receptor that has roles in resilience of neurons and memory. They found consistent expression patterns of C14orf40 and MTUS1 in carriers with risk alleles of expression SNPs and in brains of AD patients, compared with in the noncarriers and in brains of controls.
Lindsay A. Farrer, PhD, Distinguished Professor of Genetics and principal investigator of the study, said, “Our findings provide important insight about biological mechanisms leading to Alzheimer disease, especially at stages of the disease before symptoms occur. The novel genes we identified may be potential targets for developing new treatments that might delay or even prevent onset of symptoms of this insidious disease.” The study was published on December 20, 2017, in the journal Alzheimer's & Dementia.
Related Links:
Boston University School of Medicine
A new study focused on individual groups across specific on the cognitive spectrum: normal cognitive functioning or controls, mild cognitive impairment (MCI) and AD cases. As opposed to the typical study design, which combines all such persons into a single group or focuses only on cognitively healthy persons, a new study identified several novel genetic associations within multiple subgroups.
A team of scientists led by those at Boston University School of Medicine (Boston, MA, USA) conducted genome-wide association studies for AD-related endophenotypes including hippocampal volume, logical memory scores, and CSF. They tested the association between AD-related brain MRI measures, logical memory test scores and CSF levels of two AD proteins amyloid-beta (Aβ42) and tau with several million genetic markers called single-nucleotide polymorphisms (SNPs) across the genome in a sample of 1,189 participants of the Alzheimer Disease Neuroimaging Initiative (ADNI) study. They then examined the biological significance of the top-ranked associated SNPs and genes using several datasets containing information about gene expression in parts of the brain most affected by AD.
The scientists found that two of the study-wide significant genes identified in the normal cognitive functioning group, Serine/Arginine Repetitive Matrix 4 (SRRM4) and Microtubule Associated Scaffold Protein 1(MTUS1), are involved in neuronal signaling, development and loss. Another gene identified in this group, Glutamate Ionotropic Receptor NMDA Type Subunit 2B (GRIN2B), encodes a subunit of a receptor that has roles in resilience of neurons and memory. They found consistent expression patterns of C14orf40 and MTUS1 in carriers with risk alleles of expression SNPs and in brains of AD patients, compared with in the noncarriers and in brains of controls.
Lindsay A. Farrer, PhD, Distinguished Professor of Genetics and principal investigator of the study, said, “Our findings provide important insight about biological mechanisms leading to Alzheimer disease, especially at stages of the disease before symptoms occur. The novel genes we identified may be potential targets for developing new treatments that might delay or even prevent onset of symptoms of this insidious disease.” The study was published on December 20, 2017, in the journal Alzheimer's & Dementia.
Related Links:
Boston University School of Medicine
Latest Molecular Diagnostics News
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer